Scientific exchange · Dr. Hiroshi Weber

24 May 2026 · In person · Dr. Hiroshi Weber, Princess Margaret Cancer Centre · MSL James Whitfield · Lumeva

ReviewedVeeva CRMENG-0196—

Capture insight from this engagement

Location: Princess Margaret Cancer Centre
Therapeutic area: Neurology
Country: Canada
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Chronic migraine data
Switching between CGRP agents
Drug interactions

Scientific content used

CGRP class review

Questions raised

Is there guidance on switching from a monoclonal antibody?
Any data in patients with medication-overuse headache?

Notes

Scientific exchange with primary care physician at Princess Margaret Cancer Centre. Discussed chronic migraine data, switching between cgrp agents, drug interactions.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 3
Depth of exchange: 1
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0196

Audit history (0)

All create, update and approval events for this record

No audit events in sample data